European Commission grants Orphan Drug Designation to Prometic’s PBI-4050 drug for the treatment of Alström Syndrome.
Prometic’s PBI-4050 drug receives Orphan Drug Designation
European Commission grants Orphan Drug Designation to Prometic’s PBI-4050 drug for the treatment of Alström Syndrome.
Hi, this is a comment.
To get started with moderating, editing, and deleting comments, please visit the Comments screen in the dashboard.
Commenter avatars come from Gravatar.